Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis

Colin Howden, E. David Ballard, Weining Robieson

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: To compare the effectiveness of lansoprazole 30mg once daily and esomeprazole 40mg once daily on healing and symptom relief in patients with erosive oesophagitis. Design: Phase IV, randomised, double-blind, active-controlled, multicentre study. Patients and participants: 284 patients with endoscopically confirmed erosive oesophagitis (grade ≥2). Methods: Patients were randomised to treatment with lansoprazole or esomeprazole. The primary efficacy endpoint was the healing of erosive oesophagitis (defined as grade 0 or 1) at week 8. Healing rates at week 4 and the percentages of patients reporting no daytime or night-time heartburn after 1 day, 3 days and 1 week of treatment, as well as the rate of healing or improvement of oesophagitis by two grades, were also analysed. Results: Healing rates and 95% confidence intervals (CIs) at week 8 were 91.4% (85.4, 95.5%) for lansoprazole 30mg once daily and 89.1% (82.7, 93.8%) for esomeprazole 40mg once daily, respectively. For any baseline grade, greater than 90% of lansoprazole-treated and 81% of esomeprazole-treated patients exhibited healing or improvement of erosive oesophagitis by two grades from baseline to week 8. Healing rates at week 4 were also comparable: 77.0% (95% CI 69.1, 83.7%) for lansoprazole 30mg and 78.3% (95% CI 70.4, 84.8%) for esomeprazole 40mg. The percentages of heartburn-free patients after 1 day, 3 days and 1 week of treatment were slightly higher for lansoprazole compared with esomeprazole, although the differences did not reach statistical significance (p > 0.05). Both treatments were well tolerated. Conclusions: In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mg once daily are equally effective in healing erosions and relieving heartburn.

Original languageEnglish (US)
Pages (from-to)99-109
Number of pages11
JournalClinical Drug Investigation
Volume22
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Esomeprazole
Lansoprazole
Esophagitis
Heartburn
Confidence Intervals
Therapeutics
Multicenter Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. / Howden, Colin; Ballard, E. David; Robieson, Weining.

In: Clinical Drug Investigation, Vol. 22, No. 2, 01.01.2002, p. 99-109.

Research output: Contribution to journalArticle

@article{a86b2152f1bd4928929ba611cbdc119c,
title = "Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis",
abstract = "Objective: To compare the effectiveness of lansoprazole 30mg once daily and esomeprazole 40mg once daily on healing and symptom relief in patients with erosive oesophagitis. Design: Phase IV, randomised, double-blind, active-controlled, multicentre study. Patients and participants: 284 patients with endoscopically confirmed erosive oesophagitis (grade ≥2). Methods: Patients were randomised to treatment with lansoprazole or esomeprazole. The primary efficacy endpoint was the healing of erosive oesophagitis (defined as grade 0 or 1) at week 8. Healing rates at week 4 and the percentages of patients reporting no daytime or night-time heartburn after 1 day, 3 days and 1 week of treatment, as well as the rate of healing or improvement of oesophagitis by two grades, were also analysed. Results: Healing rates and 95{\%} confidence intervals (CIs) at week 8 were 91.4{\%} (85.4, 95.5{\%}) for lansoprazole 30mg once daily and 89.1{\%} (82.7, 93.8{\%}) for esomeprazole 40mg once daily, respectively. For any baseline grade, greater than 90{\%} of lansoprazole-treated and 81{\%} of esomeprazole-treated patients exhibited healing or improvement of erosive oesophagitis by two grades from baseline to week 8. Healing rates at week 4 were also comparable: 77.0{\%} (95{\%} CI 69.1, 83.7{\%}) for lansoprazole 30mg and 78.3{\%} (95{\%} CI 70.4, 84.8{\%}) for esomeprazole 40mg. The percentages of heartburn-free patients after 1 day, 3 days and 1 week of treatment were slightly higher for lansoprazole compared with esomeprazole, although the differences did not reach statistical significance (p > 0.05). Both treatments were well tolerated. Conclusions: In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mg once daily are equally effective in healing erosions and relieving heartburn.",
author = "Colin Howden and Ballard, {E. David} and Weining Robieson",
year = "2002",
month = "1",
day = "1",
doi = "10.2165/00044011-200222020-00004",
language = "English (US)",
volume = "22",
pages = "99--109",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis

AU - Howden, Colin

AU - Ballard, E. David

AU - Robieson, Weining

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: To compare the effectiveness of lansoprazole 30mg once daily and esomeprazole 40mg once daily on healing and symptom relief in patients with erosive oesophagitis. Design: Phase IV, randomised, double-blind, active-controlled, multicentre study. Patients and participants: 284 patients with endoscopically confirmed erosive oesophagitis (grade ≥2). Methods: Patients were randomised to treatment with lansoprazole or esomeprazole. The primary efficacy endpoint was the healing of erosive oesophagitis (defined as grade 0 or 1) at week 8. Healing rates at week 4 and the percentages of patients reporting no daytime or night-time heartburn after 1 day, 3 days and 1 week of treatment, as well as the rate of healing or improvement of oesophagitis by two grades, were also analysed. Results: Healing rates and 95% confidence intervals (CIs) at week 8 were 91.4% (85.4, 95.5%) for lansoprazole 30mg once daily and 89.1% (82.7, 93.8%) for esomeprazole 40mg once daily, respectively. For any baseline grade, greater than 90% of lansoprazole-treated and 81% of esomeprazole-treated patients exhibited healing or improvement of erosive oesophagitis by two grades from baseline to week 8. Healing rates at week 4 were also comparable: 77.0% (95% CI 69.1, 83.7%) for lansoprazole 30mg and 78.3% (95% CI 70.4, 84.8%) for esomeprazole 40mg. The percentages of heartburn-free patients after 1 day, 3 days and 1 week of treatment were slightly higher for lansoprazole compared with esomeprazole, although the differences did not reach statistical significance (p > 0.05). Both treatments were well tolerated. Conclusions: In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mg once daily are equally effective in healing erosions and relieving heartburn.

AB - Objective: To compare the effectiveness of lansoprazole 30mg once daily and esomeprazole 40mg once daily on healing and symptom relief in patients with erosive oesophagitis. Design: Phase IV, randomised, double-blind, active-controlled, multicentre study. Patients and participants: 284 patients with endoscopically confirmed erosive oesophagitis (grade ≥2). Methods: Patients were randomised to treatment with lansoprazole or esomeprazole. The primary efficacy endpoint was the healing of erosive oesophagitis (defined as grade 0 or 1) at week 8. Healing rates at week 4 and the percentages of patients reporting no daytime or night-time heartburn after 1 day, 3 days and 1 week of treatment, as well as the rate of healing or improvement of oesophagitis by two grades, were also analysed. Results: Healing rates and 95% confidence intervals (CIs) at week 8 were 91.4% (85.4, 95.5%) for lansoprazole 30mg once daily and 89.1% (82.7, 93.8%) for esomeprazole 40mg once daily, respectively. For any baseline grade, greater than 90% of lansoprazole-treated and 81% of esomeprazole-treated patients exhibited healing or improvement of erosive oesophagitis by two grades from baseline to week 8. Healing rates at week 4 were also comparable: 77.0% (95% CI 69.1, 83.7%) for lansoprazole 30mg and 78.3% (95% CI 70.4, 84.8%) for esomeprazole 40mg. The percentages of heartburn-free patients after 1 day, 3 days and 1 week of treatment were slightly higher for lansoprazole compared with esomeprazole, although the differences did not reach statistical significance (p > 0.05). Both treatments were well tolerated. Conclusions: In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mg once daily are equally effective in healing erosions and relieving heartburn.

UR - http://www.scopus.com/inward/record.url?scp=0036173984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036173984&partnerID=8YFLogxK

U2 - 10.2165/00044011-200222020-00004

DO - 10.2165/00044011-200222020-00004

M3 - Article

VL - 22

SP - 99

EP - 109

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 2

ER -